Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Treasury Shares (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Treasury Shares for 16 consecutive years, with $132000.0 as the latest value for Q3 2025.

  • Quarterly Treasury Shares changed 0.0% to $132000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $132000.0 through Sep 2025, changed 0.0% year-over-year, with the annual reading at $132000.0 for FY2024, 0.0% changed from the prior year.
  • Treasury Shares hit $300000.0 in Q4 2025 for Guided Therapeutics, down from $678000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $678000.0 in Q2 2021 to a low of $300000.0 in Q4 2025.
  • Historically, Treasury Shares has averaged $652800.0 across 5 years, with a median of $678000.0 in 2021.
  • Biggest YoY gain for Treasury Shares was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • Year by year, Treasury Shares stood at $132000.0 in 2021, then changed by 0.0% to $132000.0 in 2022, then changed by 0.0% to $132000.0 in 2023, then changed by 0.0% to $132000.0 in 2024, then changed by 0.0% to $132000.0 in 2025.
  • Business Quant data shows Treasury Shares for GTHP at $132000.0 in Q3 2025, $132000.0 in Q2 2025, and $132000.0 in Q1 2025.